期刊文献+

耐碳青霉烯鲍曼不动杆菌感染治疗的实验依据 被引量:2

The experimental proof of treating infection caused Acinetobacter banmamii with carbapenem resistance
下载PDF
导出
摘要 目的分析一株鲍曼不动杆菌耐碳青霉烯类抗生素的机制。方法用三维试验检测碳青霉烯酶,用聚合酶链反应(PCR)扩增和产物测序方法确认耐碳青霉烯酶类抗生素的机制;采用微量肉汤稀释法测定头孢哌酮/舒巴坦和左旋氧氟沙星的MIC值,应用棋盘格局法检测头孢哌酮/舒巴坦和左旋氧氟沙星的联合抗菌效应,计算FIC指数。结果三维试验显示该菌株产碳青霉烯酶,经分子生物学确认有blaOXA-23基因;头孢哌酮/舒巴坦的MIC值为64μg/ml,左旋氧氟沙星的MIC值为32μg/ml,两者联合使用后其MIC都下降一个梯度,计算得FIC=1。结论该菌株产OXA-23碳青霉烯酶,头孢哌酮/舒巴坦与左旋氧氟沙星联合使用后,表现为相加作用。 Object To analyze the cause of Acinetobacter banmamii resisting to carbapenem agent and detect the combinated effect of cefoperazone/sulbactam and levofloxacin. Methods Three-dimension and PCR methods were used to analyze the of mechanism of resisting to carbapenem; The combination effects were deetected by antibiotic susceptibility tests. Resuits blaOXA-23 gene was confirmed in Acinetobacter banmamii; antibiotic sensitive tests showed that cefoperazone/sulbactam's MIC was 64 μg/ml and levofloxacin's MIC was 32 μg/m. The FIC equal 1 after using both agensts. Conclusion Acinetobacter banmamii can produce OXA-23 carbapenase. There is add effect after combination treatment with cefoperazone/sulbactam and levofloxacin.
出处 《江西医学检验》 2006年第5期406-408,共3页 Jiangxi Journal of Medical Laboratory Sciences
关键词 三维试验 OXA-23基因 碳青霉烯类 鲍曼不动杆菌 联合药敏 Three-dimensional test OXA-23 gene Cefoperazone/sulbactam Levofloxacin Acinetobacter banmamii Combination of antibiotic susceptibility test
  • 相关文献

参考文献5

  • 1Afza12Shah M,Woodford N,Livermore DM.Characterization of OXA-25,OXA-26,and OXA-27 molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii[J].Antimicrob Agents Chemother,2001,45:583 ~ 588.
  • 2National Committee for Clinical Laboratory Standards.Performance standards for antimicrobial susceptibility testing[J].Fourteenth informational supplement,2004,M 100-S 14.
  • 3陈东科,彭红,张秀珍.医院内不动杆菌产酶耐药表型研究[J].临床检验杂志,2004,22(1):28-31. 被引量:29
  • 4王辉,陈民钧.碳青霉烯酶:未来困扰我们的难题[J].中华内科杂志,2003,42(5):354-356. 被引量:62
  • 5Bou G,Oliver A,Martines-Beltran J.OXA-24,a novel class D beta-lactamase with carbapenemase activity an Acinetobacter baumannii clinical strain[J].J AAC,2000,44:1556 ~ 1561.

二级参考文献28

  • 1Tsakris A, Pournaras S, Woodford N, et al. Outbreak d infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol, 2000.38: 1290-1292.
  • 2Poirel L, Naas T, Nicolas D, et al. Characterization d VIM-2, a carbapanem-hydrolyzing metallo-beta-lactamase and its plasmid-and integron-borne gene from a Psedomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother. 2000.44: 891-897.
  • 3Yah J, Hsueh P, Ko W, et al. Metallo-beta-lactamase in clinical Psedumonas isolates in Taiwan and identification d VIM-3, a novel variant of VIM-2 enzyme. Antimicrob Agents Chemother, 2001,45 :2224-2228.
  • 4Yum JH, Yi K, Lee H, et al. Molecular characterization of metallobeta-lactamase-producing Acinetobacter bsumannii and Acinetobacter genomospecies 3 from Korea: identification of two new integrons carrying the bla (VIM-2) gene cassettes. J Antimicrob Chemother,2002, 49: 837-840.
  • 5Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother, 2000, 44:1556-1561.
  • 6Afzal-Shah M,Woodford N,Liermore DM,Characterization of OXA-25,OXA-26,and OXA-27,molecular class D bet-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii.Antimicrob Agents Chemother,2001,45:583-588.
  • 7Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect, 2002, 8: 321-331.
  • 8Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol, 2000, 3:489-495.
  • 9Bush K. Metallo-beta-lactamases: a class apart. Clin Infect Dis,1998, 27 Suppl 1 :S48-53.
  • 10Rasmussen BA, Bush K. Carbapenem-hydrolyzing bots-Isctamases.Antimicrob Agents Chemother, 1997, 41:223-232.

共引文献89

同被引文献28

  • 1蔡挺,陈童恩,刘鹏,许小敏,陈琳.舒普深联合胸腺肽α_1治疗耐碳青酶烯类鲍曼不动杆菌肺炎[J].中华急诊医学杂志,2006,15(6):562-564. 被引量:5
  • 2俞碧霞,杨青,干文君.鲍曼不动杆菌5年间菌株分布及耐药性变迁[J].上海预防医学,2006,18(8):366-367. 被引量:25
  • 3石岩,刘大为,许大波,徐英春,陈民均,王辉.泛耐药鲍曼不动杆菌感染临床治疗初探[J].中国感染与化疗杂志,2007,7(1):34-37. 被引量:112
  • 4Hsueh PR,Teng LJ,Chen CY,et al.Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital,Taiwan[J].Emerg Infect Dis,2002,8(8):827-832.
  • 5Limansky AS,Zamboni MI,Guardati MC,et al.Evaluation of phenotypic and genotypic markers for clinical strains of Acinetobacter baumannii[J].Medicina (B Aires),2004,64(4):306-312.
  • 6Adams MD,Goglin K,Molyneaux N,et al.Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii[J].J Bacteriol,2008,190(24):8053-8064.
  • 7Fass RJ,Gregory WW,D'amato RF,et al.In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family ecterobacteriaceae and nonfermenters[J].Antimicrob Agents Chemother,1990,34(11):2256-2259.
  • 8Corvekka X,Ariza J,Ardanuy C,et al.Efficacy of sulbactam alone and combination with ampicilin in nosocomial infections caused by multiresistant Acinetobacter baumannii[J].J Antimicrob Chemother,1998,42(6):793-802.
  • 9Betrosian AP,Frantzeska F,Xanthaki A,et al.Highdose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii[J].Scandinavian J Infect Dis,2007,39(1):38-43.
  • 10Michalopoulos A,Fotakis D,Virtzili S,et al.Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria:a prospective study[J].Respir Med,2008,102(3):407-412.

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部